FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, D.C. 20549 | |
|------------------------|--|
|------------------------|--|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| | OMB APPROVAL | | | | | | | | | |
|--|---|-----|--|--|--|--|--|--|--|--|
| | OMB Number: 3235-028 Estimated average burden | | | | | | | | | |
| | | | | | | | | | | |
| | hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Thistle Mary | | | | 2. Issuer Name and Ticker or Trading Symbol Vigil Neuroscience, Inc. [VIGL] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | | | |
|--|--|------------|------------------|---|---|--|--|-----|-------------------|--|-----------------------------|---|--|--|-----------------------------------|--|--|---|--|--|
| | EUROSCI | ENCE, INC. | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 04/18/2022 | | | | | | | - | Λ | Officer (give title below) | | | Other (s below) | | | |
| 1 BROADWAY, 7TH FLOOR, SUITE 07-300 | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) CAMBRIDGE MA 02142 | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | | |
| (City) | (S | tate) | (Zip) | | | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da | | | | | Execution Date, | | Code (Instr. 5) | | | | 4 and Securitie Benefici | | es For ally (D) Following (I) (I | | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | |
| | | | | | | | Code | v | Amount | (A) or (D) | Pric | се | Transact (Instr. 3 a | tion(s) | | | msu. 4) | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| | | | ransad ode (l | | n of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title an of Securit Underlyin Derivative (Instr. 3 an | ies g Securi | 1 | 3. Price of Derivative Security Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | c | ode | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | Amou or Numb of Share | per | | | | | | |
| Stock Option Grant (Right to Buy) | \$6.8 | 04/18/2022 | | | A | | 24,309 | | (1) | 0 | 04/18/2032 | Common Stock | 24,30 | 09 | \$0.00 | 24,309 |) | D | | |

Explanation of Responses:

1. 25% of the shares subject to this option shall vest and become exercisable on April 18, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

Remarks:

/s/ Jennifer Ziolkowski, 04/20/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.